Investigational drug · Phase 3
BFB759
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "BFB759"
First trial start
2025
Jul 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BFB759", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis (AD)
- Hidradenitis Suppurativa (HS)
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Hidradenitis suppurativa · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "BFB759" as an intervention, largest first.
- A Study Evaluating BFB759 in Moderate to Severe Atopic DermatitisPivotal-lookingActive, not recruiting
Bluefin Biomedicine, Inc.Industry
NCT07105488 · 225 participants (planned) · Start Jul 15, 2025 · Primary completion Feb 28, 2027
Drug: BFB759; Placebo · For: Atopic Dermatitis (AD)
Sites: Phoenix, Arizona; Encino, California; Huntington Beach, California · 88 sites in all
- A Study Evaluating BFB759 in Moderate to Severe Hidradenitis SuppurativaPivotal-lookingActive, not recruiting
Bluefin Biomedicine, Inc.Industry
NCT07287644 · 210 participants (planned) · Start Nov 3, 2025 · Primary completion Aug 1, 2027
Drug: BFB759 · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Encino, California; Huntington Beach, California · 64 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Atopic Dermatitis (AD)
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- QY201Phase 33 trials
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Adult Subjects With Non-Segmental Vitiligo, Atopic Dermatitis (AD), Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)
- MH004Phase 32 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Vitiligo, Atopic Dermatitis (AD)
- GS101Phase 31 trial
Jiangsu Genscend Biopharmaceutical Co., Ltd · Atopic Dermatitis (AD)
- ENV-294Phase 23 trials
Enveda Therapeutics · Atopic Dermatitis (AD), Atopic Dermatitis, Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.